Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Azathioprine 150mg/5ml oral liquid
0802010G0AABYBY
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 15mg/5ml oral liquid
0802010G0AAAUAU
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 17.5mg/5ml oral liquid
0802010G0AABDBD
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 175mg/5ml oral liquid
0802010G0AABJBJ
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 17mg/5ml oral liquid
0802010G0AABKBK
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 2.5mg/5ml oral liquid
0802010G0AACBCB
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 20mg/5ml oral solution
0802010G0AAAWAW
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 30mg capsules
0802010G0AABRBR
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 35mg/5ml oral liquid
0802010G0AABEBE
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 37.5mg/5ml oral liquid
0802010G0AABFBF
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 40mg/5ml oral liquid
0802010G0AAAQAQ
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 45mg/5ml oral liquid
0802010G0AABABA
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 4mg/5ml oral liquid
0802010G0AABTBT
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 50mg powder for solution for injection vials
0802010G0AAAAAA
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 5mg capsules
0802010G0AABPBP
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 5mg/5ml oral liquid
0802010G0AAAYAY
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 60mg/5ml oral liquid
0802010G0AABGBG
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 65mg/5ml oral suspension
0802010G0AACLCL
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 70mg/5ml oral liquid
0802010G0AABZBZ
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 7mg/5ml oral liquid
0802010G0AABBBB
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 80mg/5ml oral liquid
0802010G0AACCCC
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Azathioprine 90mg/5ml oral liquid
0802010G0AACDCD
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Basiliximab 10mg inj vials
0802020D0AAABAB
|
Basiliximab | Basiliximab | Malignant Disease and Immunosuppression | No data available |
|
Basiliximab 20mg inj vials
0802020D0AAAAAA
|
Basiliximab | Basiliximab | Malignant Disease and Immunosuppression | No data available |
|
Basiliximab 20mg powder for solution for injection vials
0802020D0AAACAC
|
Basiliximab | Basiliximab | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.